Lipidio Pharmaceuticals, a San Diego, CA-based biopharmaceutical company developing novel therapeutics for dermatological and metabolic diseases, raised a Series A Extension financing, binging the total over $20M.
In addition to current Series A investors, this extension was led with participation of several new investors, including Nancy Chang (former Founder and CEO of Tanox), John Maraganore (former Founding CEO of Alnylam) and Brent Saunders (former Chairman & CEO of Allergan), along with a selected group of world-renowned dermatologists. Previous investors in the Series A include other successful, serial entrepreneur biopharma executives, as well as two Institutional Investor firms, Alethea Capital and 3E Bioventures.
Led by CEO J. Gordon Foulkes, Lipidio Pharmaceuticals is a biopharmaceutical company focused on transforming molecules into the right medicines for dermatological and metabolic diseases. The company’s lead program, GDD3898, is in clinical development for the treatment of multiple conditions with unmet medical needs including dermatological conditions such as moderate to severe acne and sebaceous hyperplasia, nonalcoholic steatohepatitis (NASH), and obesity.
FinSMEs
10/11/2022